치료 저항성 우울증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global treatment-resistant depression treatment market size is expected to reach USD 8.03 Billion in 2034 from USD 3.08 Billion in 2025, growing at a CAGR of 11.23% during 2026-2034.This market is witnessing strong growth as the prevalence of Treatment-Resistant Depression continues to rise globally. This condition affects individuals who do not respond adequately to conventional antidepressant treatments, creating a need for advanced and alternative therapeutic approaches. Increasing awareness about mental health and the growing burden of depression are key factors driving market demand.

The market is driven by innovations in treatment modalities, including novel pharmacological therapies, neuromodulation techniques, and psychotherapy approaches. The introduction of fast-acting antidepressants and therapies such as ketamine-based treatments has significantly improved treatment outcomes. Additionally, increasing healthcare investments and supportive government initiatives aimed at mental health awareness are contributing to market growth.

Future prospects for this market are highly promising, with ongoing research focused on developing more effective and personalized treatment options. Advancements in brain stimulation technologies and digital therapeutics will further enhance patient care. Growing acceptance of mental health treatment and reduced stigma will encourage more individuals to seek help. As the need for effective solutions continues to rise, the treatment-resistant depression market is expected to expand significantly.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Type

• N-methyl-D-aspartate (NMDA)
• Antidepressants
• Antipsychotics
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Johnson & Johnson, Sage Therapeutics, Biogen, Axsome Therapeutics, AbbVie, Otsuka Pharmaceutical, H. Lundbeck, Compass Pathways, GH Research, Cybin, MindMed, atai Life Sciences, Relmada Therapeutics, Neumora Therapeutics, Beckley Psytech, Delix Therapeutics, Supernus Pharmaceuticals, Takeda, Pfizer, Eli Lilly

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. N-methyl-D-aspartate (NMDA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antidepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antipsychotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Stores & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Type
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Type
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Spain
  • 6.3.8 Russia
  • 6.3.9 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Type
  • 6.4.2 By Distribution Channel
  • 6.4.3 China
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 India
  • 6.4.7 Australia
  • 6.4.8 South East Asia
  • 6.4.9 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Type
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Type
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Johnson & Johnson
  • 8.2.2 Sage Therapeutics
  • 8.2.3 Biogen
  • 8.2.4 Axsome Therapeutics
  • 8.2.5 AbbVie
  • 8.2.6 Otsuka Pharmaceutical
  • 8.2.7 H. Lundbeck
  • 8.2.8 Compass Pathways
  • 8.2.9 GH Research
  • 8.2.10 Cybin
  • 8.2.11 MindMed
  • 8.2.12 Atai Life Sciences
  • 8.2.13 Relmada Therapeutics
  • 8.2.14 Neumora Therapeutics
  • 8.2.15 Beckley Psytech
  • 8.2.16 Delix Therapeutics
  • 8.2.17 Supernus Pharmaceuticals
  • 8.2.18 Takeda
  • 8.2.19 Pfizer
  • 8.2.20 Eli Lilly